Equities analysts expect that vTv Therapeutics (NASDAQ:VTVT) will post earnings per share of ($0.37) for the current quarter, according to Zacks. Three analysts have made estimates for vTv Therapeutics’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.45). vTv Therapeutics reported earnings per share of ($0.44) during the same quarter last year, which would indicate a positive year over year growth rate of 15.9%. The business is expected to announce its next quarterly earnings results on Wednesday, May 2nd.
According to Zacks, analysts expect that vTv Therapeutics will report full year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.85) to ($0.70). For the next financial year, analysts expect that the firm will post earnings of ($0.99) per share, with EPS estimates ranging from ($2.84) to $0.08. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.03). The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.10 million.
Several analysts recently issued reports on VTVT shares. Canaccord Genuity set a $15.00 price target on vTv Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 21st. Zacks Investment Research upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, April 13th. Northland Securities started coverage on vTv Therapeutics in a research note on Thursday, February 8th. They issued an “outperform” rating and a $28.00 price target for the company. Roth Capital started coverage on vTv Therapeutics in a research note on Thursday, March 8th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Seaport Global Securities started coverage on vTv Therapeutics in a research note on Thursday, March 29th. They issued a “buy” rating and a $14.00 price target for the company. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $13.69.
Shares of NASDAQ VTVT traded down $0.09 during midday trading on Thursday, hitting $2.11. 10,220,730 shares of the company’s stock were exchanged, compared to its average volume of 939,429. The company has a market capitalization of $39.05, a P/E ratio of -1.26 and a beta of 1.74. vTv Therapeutics has a 12 month low of $0.65 and a 12 month high of $8.40. The company has a current ratio of 0.76, a quick ratio of 0.76 and a debt-to-equity ratio of -0.10.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning bought a new stake in vTv Therapeutics in the 4th quarter valued at $114,000. Millennium Management LLC bought a new stake in shares of vTv Therapeutics during the 4th quarter valued at $377,000. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics during the 3rd quarter valued at $481,000. State Street Corp lifted its position in shares of vTv Therapeutics by 2.1% during the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares during the period. Finally, Royce & Associates LP bought a new stake in shares of vTv Therapeutics during the 4th quarter valued at $1,352,000. Institutional investors and hedge funds own 11.20% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.